Morrison Foerster has advised Ollin Biosciences, Inc. ("Ollin"), a privately-held clinical-stage biopharmaceutical company developing therapies for serious eye diseases, on patent matters related to its definitive agreement to be acquired by Johnson & Johnson for $2.2 billion upfront with the potential for up to approximately $1.1 billion in additional regulatory and commercial milestone payments.
The MoFo team advising Ollin is led by patent strategy + prosecution partners Catherine Polizzi and Jie Zhou.